A pill just passed its first human trial mimicking one exercise hormone. A real sprint moves hundreds.

Enveda reported Phase 1 results for ENV-308, a pill designed to mimic Lac-Phe, a hormone the body releases during high-intensity exercise. It was well tolerated and lowered circulating leptin. It did not reproduce what a workout does to the rest of your blood chemistry.

The gist
Enveda reported Phase 1 results for ENV-308 on August 18, 2026: 88 healthy volunteers, no serious adverse events, discontinuations, or dose interruptions.
ENV-308 is designed to mimic N-lactoyl-phenylalanine (Lac-Phe), a hormone the body releases during high-intensity exercise and links to appetite suppression.
The only confirmed biological signal was a drop in circulating leptin, largest in volunteers who started with the highest leptin levels for their sex. Enveda's own release calls this signal exploratory.
The company is developing ENV-308 for people trying to hold their weight after stopping a GLP-1 drug. The trial did not show it causes weight loss, builds muscle, or improves fitness.

One hormone, one pill. Enveda announced Phase 1 results for ENV-308 on August 18, 2026. Across 88 healthy volunteers, the drug was well tolerated at every dose tested, with no serious adverse events, discontinuations, or dose interruptions, including the gastrointestinal side effects that push people off GLP-1 drugs like semaglutide.

Lac-Phe is the target. ENV-308 is built to mimic N-lactoyl-phenylalanine, a hormone the body produces in higher amounts during intense exercise and after eating. Earlier research linked it to appetite suppression, including weight loss in obese mice given the compound directly.

Leptin moved. Nothing else confirmed did. The trial's one biological readout was a reduction in circulating leptin, a hormone that signals fat stores to the brain. The effect was largest in volunteers who started with the highest leptin levels relative to their sex. Enveda's release calls this an exploratory signal, not proof the drug changes appetite or weight in people.

The market it's aimed at. Enveda plans a Phase 2 trial testing whether ENV-308 helps people keep weight off after they stop taking a GLP-1 drug, the regain problem that shows up once semaglutide or tirzepatide stops. That is a maintenance play, not a replacement for the injections.

A sprint moves 721 proteins. This pill targets one. Lac-Phe is one of the molecules that surged in a Cell Reports Medicine study on sprint intervals, where six 30-second sprints shifted 721 of 2,884 detected blood proteins immediately, against seven after 90 minutes of moderate cycling. That study noted none of those proteins sit on a standard blood panel. ENV-308 tries to isolate and reproduce one of them in pill form. Whatever the rest of that proteomic shift does for the body, this trial did not test it.

Not the same thing as exercise. Enveda's own materials state the trial did not show ENV-308 causes weight loss, builds muscle, or improves fitness. A safety trial in 88 people establishes that the pill is tolerated. It does not establish that swallowing it does what six sprints do.

Why this matters for you

Curious what exercise habits actually move on a standard blood panel over time, not one isolated hormone? See what a Cell Reports Medicine study found sprints do to hundreds of blood proteins at once.

Disclaimer
This is commentary on published research, not medical advice. Talk to your doctor before changing anything based on a study.
Free · No account · 45 seconds

See what your own panel actually measures

Upload your blood report and see which markers were tested, what they mean, and what a standard panel leaves out.

Analyze My Blood Test →
Any lab PDF or phone photo · Processed in memory, never stored